Antiphospholipid syndrome and challenges with direct oral anticoagulants

Area of Science:

• Hematology and Immunology
• Pharmacology and Therapeutics

Background:

• Direct oral anticoagulants (DOACs) are standard for venous thromboembolism (VTE) and atrial fibrillation management.
• Long-term anticoagulation is crucial for high-risk patients, including those with antiphospholipid syndrome (APS).
• 'Triple positive' APS (lupus anticoagulant, anti-β2-glycoprotein-1, anti-cardiolipin antibodies) indicates highest thrombotic risk.

Purpose of the Study:

• To review the diagnosis of thrombotic antiphospholipid syndrome (APS).
• To explore strategies for antiphospholipid antibody testing during anticoagulation.
• To evaluate the safety and efficacy of DOACs in thrombotic APS patients.

Main Methods:

• Review of meta-analyses and randomized control trials.
• Analysis of diagnostic criteria for thrombotic APS.
• Examination of testing protocols during anticoagulation therapy.

Main Results:

• Concerns exist that DOACs may be less effective than vitamin K antagonists (VKAs) in preventing thrombosis in APS.
• This potential reduced efficacy is particularly noted in 'triple positive' APS patients.
• Evidence on DOAC safety in this specific patient group is under scrutiny.

Conclusions:

• Current evidence suggests DOACs might be less effective than VKAs for thrombotic APS, especially 'triple positive' cases.
• Further research is needed to clarify optimal anticoagulation strategies for these high-risk patients.
• Implications for managing unprovoked VTE in the context of APS require careful consideration.